A prospective randomized trial of labor induction with vaginal controlled-release dinoprostone inserts with or without oxytocin and misoprostol+oxytocin.
OBJECTIVE
This study was designed in an aim to compare the efficacies of three labor induction methods, dinoprostone (PGE2) vaginal insert with or without concomittant oxytocin and misoprostol (PGE1) combined with oxytocin infusion.


METHODS
This was a prospective observational trial of nulliparous women undergoing labor induction from December 2006 to January 2007. Inclusion criteria were: gestational age between 36 to 42 weeks, singleton cephalic presentation of the fetus, intact membrane and unfavorable cervical Bishop score < 6, and absence of spontaneous uterine contractions. Participants were then randomly assigned to preinduction cervical ripening with a dinoprostone vaginal insert (10 mg) administered into the posterior fornix for a total of 12 hours without oxytocin (group I); with oxytocin (group II), and with misoprostol (50 microg) intravaginally in the posterior fornix with repeat dosing at 6-hour intervals with a maximum dose of four with oxytocin (group III).


RESULTS
A total number of 106 women met the inclusion criteria without distribution for 19 cases in group I, 44 and 43 cases in groups II and III, respectively. There were no statistically significant differences in terms of the demographic characteristics, indication of labor induction, interval from-induction-to-delivery, cardiotocographic abnormalities and neonatal outcomes and mode of deliveries among the three groups (p > 0.05).


CONCLUSIONS
Three methods of labor induction were equally efficient in achieving succesful delivery without any maternal and fetal adverse outcomes.
Tanir
H M
HM
Department of Obstetrics and Gynecology, Perinatology Unit, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey. mtanir@superonline.com
Sener
T
T
Yildiz
C
C
Kaya
M
M
Kurt
I
I
D000282:Administration, Intravaginal; D000328:Adult; D001034:Apgar Score; D036861:Delivery, Obstetric; D015232:Dinoprostone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D016595:Misoprostol / Q000627:therapeutic use*; D010120:Oxytocics / Q000008:administration & dosage*; D010121:Oxytocin / Q000627:therapeutic use*; D010298:Parity; D011247:Pregnancy; D011446:Prospective Studies
D010120:Oxytocics; D016595:Misoprostol; D010121:Oxytocin; D015232:Dinoprostone